Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 8/20 | 0.64 |
| ▸ | NPY4R | P50391 | 8/20 | 0.64 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.64 |
| ▸ | NPY1R | P25929 | 6/20 | 0.64 |
| ▸ | TFPI | P10646 | 4/20 | 0.61 |
| ▸ | CALCR | P30988 | 3/20 | 0.60 |
| ▸ | KDM1A | O60341 | 2/20 | 0.60 |
| ▸ | MAOB | P27338 | 1/20 | 0.60 |
| ▸ | KDM5A | P29375 | 1/20 | 0.60 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29811066 | 0.94 | KDM1A (0.69) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL30658322 | 0.92 | NPY2R (0.68) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL31182743 | 0.92 | NPY2R (0.66) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL31182900 | 0.91 | CALCR (0.67) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL31295738 | 0.91 | TFPI (0.64) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL29523674 | 0.90 | CALCR (0.70) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL31182587 | 0.90 | NPY2R (0.66) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL30834205 | 0.90 | NPY2R (0.66) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL30432811 | 0.90 | NPY2R (0.60) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL30607346 | 0.90 | CALCR (0.60) | NPY2RNPY4RNPY5RNPY1RTFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629409-B2 | Vaccine | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2026-05-19 | — | — | US | disclosed |
| US-20240226261-A9 | VACCINE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-07-11 | — | — | US | disclosed |
| US-20240131136-A1 | VACCINE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-04-25 | — | — | US | disclosed |
| US-11844828-B2 | Vaccine | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-12-19 | — | — | US | disclosed |
| US-20230248816-A9 | PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-08-10 | — | — | US | disclosed |
| US-20230066762-A1 | IMMUNOGENIC COMPOSITION | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-03-02 | — | — | US | disclosed |
| US-20220288190-A1 | PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-09-15 | — | — | US | disclosed |
| US-20220152182-A1 | VACCINE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-05-19 | — | — | US | disclosed |
| US-11266731-B2 | Vaccine | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220288190-A1 | PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE | CFD, PEPD, SERPINA6 | NPY2R 2991/4885NPY4R 3062/4885NPY5R 3179/4885 |
| US-20230248816-A9 | PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE | CFD, PEPD, SERPINA6 | NPY2R 2991/4885NPY4R 3062/4885NPY5R 3179/4885 |
| US-12629409-B2 | Vaccine | MRPL21, STT3B, CD47 | NPY2R 658/4885NPY4R 1069/4885NPY5R 245/4885 |
| US-20230066762-A1 | IMMUNOGENIC COMPOSITION | CXCL10, CCL2, CCL11 | NPY2R 3202/4885NPY4R 3821/4885NPY5R 3232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.